Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.

Stock Quote Disclaimer: Copyright © 1998-2002 MarketWatch.com Inc. User agreement applies. Historical and current end-of-day data provided by Interactive Data Corp. Intraday data is at least 20-minutes delayed. All times are EDT. Intraday data provided by S&P Comstock and subject to terms of use.

NYSE | BMY 21.97 | +0.37 | 4:02 PM EDT | 15 May 2008

Top Stories

Nordic Capital and
Avista Capital Partners
to Acquire ConvaTec
for Approximately $4.1 Billion
Read more >>

Uninsured and Need Help Paying for Your Bristol-Myers Squibb Cancer Medicine?
A new website launched this month helps cancer patients who cannot afford their Bristol-Myers Squibb medicine. Read more >>

Latest News
05.15.2008>>New Data on Bristol-Myers Squibb Oncology Compounds to Be Featured in More Than 100 Abstracts at ASCO 2008 05.13.2008>>Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease 05.08.2008>>ABILIFY(R) (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (Aged 13-17) With Schizophrenia